Cidara buys back flu rights, sells an­ti­fun­gal and inks $240M PIPE

Cidara Ther­a­peu­tics an­nounced sev­er­al sweep­ing moves on Wednes­day af­ter­noon to bring an in­fluen­za drug back in-house and raise mon­ey from in­vestors to back the pro­gram …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.